Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...

Patients with suspected new bladder cancer were randomly assigned 1:1 to transurethral resection of bladder tumor or ...